Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 5/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | RPA1 | P27694 | 2/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30806841 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AKDM4EGLA | |
| SCHEMBL20168500 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AKDM4EGLA | |
| SCHEMBL30597783 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AKDM4EGLA | |
| SCHEMBL31493437 | 0.82 | MEN1 (0.36) | ALDH1A1MEN1KMT2AKDM4EGLA | |
| SCHEMBL8563062 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AKDM4EGLA | |
| SCHEMBL25243517 | 0.78 | MAPT (0.48) | ALDH1A1MEN1KMT2AKDM4EPKM | |
| SCHEMBL31207823 | 0.78 | MAPT (0.48) | ALDH1A1MEN1KMT2AKDM4EPKM | |
| SCHEMBL5858987 | 0.75 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AKDM4EGLA | |
| SCHEMBL26109688 | 0.75 | MEN1 (0.46) | ALDH1A1MEN1KMT2AKDM4EGLA | |
| SCHEMBL31221795 | 0.74 | WNT1 (0.33) | ALDH1A1MEN1KMT2AKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562018-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Biogen MA Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-118271336-A | Preparation method of 6-chlorothieno [2,3-b ] pyridine-2-carboxylic acid | 南京药石科技股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271336-A | Preparation method of 6-chlorothieno [2,3-b ] pyridine-2-carboxylic acid | 南京药石科技股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271336-A | Preparation method of 6-chlorothieno [2,3-b ] pyridine-2-carboxylic acid | 南京药石科技股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024026061-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023194458-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023111005-A1 | CARBOXAMIDE SUBSTITUTED HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | WMT AG (DE) | 2023-06-22 | — | — | WO | disclosed |
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2018-05-24 | — | — | US | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-3297437-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187324-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TD2, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187324-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TD2, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ALDH1A1 2699/4885MEN1 1098/4885KMT2A 1242/4885 |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ALDH1A1 2699/4885MEN1 1098/4885KMT2A 1242/4885 |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ALDH1A1 2699/4885MEN1 1098/4885KMT2A 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.